- Posted by Melinda L on July 27, 2013 at 4:30pm
It only takes a few minutes to make a call and make a difference!
The FDA recently issued a draft guidance on the Expedited Approval Programs which they say fulfills the does not address specific issues related to rare disease drug development as required by FDASIA. This is unacceptable! mandate on Accelerated Approval for Rare Diseases, however the guidance
URGENT ACTION is needed from the patient community to ask Members of Congress to sign onto the Congressional Letter urging FDA to improve access to Accelerated Approval for Rare Diseases! Please take five minutes to call and/ or email your Member of Congress today!
Not sure who your representative is, just click here:
Call and ask to speak to the staffer who works on Healthcare issues.
You can use the following script. Just add your information:
Hello my name is [ — ] and I live in [ —- ] As a constituent , I am [calling /writing] regarding an urgent request for my Representative, [Rep. ??], to sign onto the Congressional letter urging the FDA to fully implement the rare disease requirements in the Food & Drug Administration Safety and Innovation Act known as FDASIA. As someone who struggles [or has a child] from the effects of CMT, a degenerative neuromuscular disorder, this issue is very important to me.
The letter simply asks the FDA to ensure that rare diseases have access to the Accelerated Approval pathway, which is required by FDASIA. To sign onto the letter please contact Tom Power in Rep. Bilirakis’ office 202-225-5755. Thank you for your time.
To find out more information about the FDA’s draft guidance, FDASIA and Accelerated Approval go to: www.everylifefoundation.org/action-alert-accelerated-approval
- A New FDA for the Age of Personalized, Molecular Medicine (marginalrevolution.com)
- Drug Companies Rejoice In ‘Breakthrough Therapy’ Designation; How It Brings Lifesaving Drugs To People More Quickly (medicaldaily.com)